These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 9607216)
1. RNA metabolism in uremic patients: accumulation of modified ribonucleosides in uremic serum. Technical note. Niwa T; Takeda N; Yoshizumi H Kidney Int; 1998 Jun; 53(6):1801-6. PubMed ID: 9607216 [TBL] [Abstract][Full Text] [Related]
2. Liquid-chromatographic profiling of solutes in serum of uremic patients undergoing hemodialysis and chronic ambulatory peritoneal dialysis (CAPD); high concentrations of pseudouridine in CAPD patients. Schoots AC; Gerlag PG; Mulder AW; Peeters JA; Cramers CA Clin Chem; 1988 Jan; 34(1):91-7. PubMed ID: 3338190 [TBL] [Abstract][Full Text] [Related]
3. Serum and erythrocyte tocopherol in uremic patients: effect of hemodialysis versus peritoneal dialysis. Pastor MC; Sierra C; Bonal J; Teixidó J Am J Nephrol; 1993; 13(4):238-43. PubMed ID: 8267019 [TBL] [Abstract][Full Text] [Related]
4. The influence of uremic serum on interleukin-1beta and interleukin-1 receptor antagonist production by peripheral blood mononuclear cells. Higuchi T; Fukuda N; Yamamoto C; Yamazaki T; Oikawa O; Ohnishi Y; Okada K; Soma M; Matsumoto K Ther Apher Dial; 2006 Feb; 10(1):65-71. PubMed ID: 16556139 [TBL] [Abstract][Full Text] [Related]
5. Accumulation of indoxyl-beta-D-glucuronide in uremic serum: suppression of its production by oral sorbent and efficient removal by hemodialysis. Niwa T; Miyazaki T; Tsukushi S; Maeda K; Tsubakihara Y; Owada A; Shiigai T Nephron; 1996; 74(1):72-8. PubMed ID: 8883023 [TBL] [Abstract][Full Text] [Related]
6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
7. Reticulated platelets in uremic patients: effect of hemodialysis and continuous ambulatory peritoneal dialysis. Tàssies D; Reverter JC; Cases A; Escolar G; Villamor N; López-Pedret J; Castillo R; Ordinas A Am J Hematol; 1995 Nov; 50(3):161-6. PubMed ID: 7485076 [TBL] [Abstract][Full Text] [Related]
8. Oxalic Acid as a uremic toxin. Mydlík M; Derzsiová K J Ren Nutr; 2008 Jan; 18(1):33-9. PubMed ID: 18089441 [TBL] [Abstract][Full Text] [Related]
9. The determination of insulin sensitivity in hemodialysis and continuous ambulatory peritoneal dialysis in nondiabetic patients with end-stage renal disease. Tuzcu A; Bahceci M; Yilmaz ME; Turgut C; Kara IH Saudi Med J; 2005 May; 26(5):786-91. PubMed ID: 15951871 [TBL] [Abstract][Full Text] [Related]
10. High serum lipoprotein(a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis. Shoji T; Nishizawa Y; Nishitani H; Yamakawa M; Morii H Clin Nephrol; 1992 Nov; 38(5):271-6. PubMed ID: 1451340 [TBL] [Abstract][Full Text] [Related]
11. Uremic pruritus in patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). The role of plasma histamine and skin mast cells. Mettang T; Fritz P; Weber J; Machleidt C; Hübel E; Kuhlmann U Clin Nephrol; 1990 Sep; 34(3):136-41. PubMed ID: 1699691 [TBL] [Abstract][Full Text] [Related]
13. Does dialysis modality influence the oxidative stress of uremic patients? Capusa C; Stoian I; Rus E; Lixandru D; Barbulescu C; Mircescu G Kidney Blood Press Res; 2012; 35(4):220-5. PubMed ID: 22223182 [TBL] [Abstract][Full Text] [Related]
14. Effects of azathioprine and mizoribine on aggregation of normal and uremic platelets. Malyszko JS; Malyszko J; Pawlak K; Mysliwiec M; Takada Y; Takada A Transplant Proc; 1996 Dec; 28(6):3488-9. PubMed ID: 8962356 [No Abstract] [Full Text] [Related]
15. Loss of phospholipids asymmetry in red blood cells contributes to anemia in uremic patients. Kong QY; Wu X; Li J; Peng WX; Ye R; Lindholm B; Wang T Adv Perit Dial; 2001; 17():58-60. PubMed ID: 11510298 [TBL] [Abstract][Full Text] [Related]
16. The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels. Borazan A; Ustün H; Ustundag Y; Aydemir S; Bayraktaroglu T; Sert M; Yilmaz A Mediators Inflamm; 2004 Jun; 13(3):201-4. PubMed ID: 15223612 [TBL] [Abstract][Full Text] [Related]
17. Serum leptin, resistin, and lipid levels in patients with end stage renal failure with regard to dialysis modality. Taskapan MC; Taskapan H; Sahin I; Keskin L; Atmaca H; Ozyalin F Ren Fail; 2007; 29(2):147-54. PubMed ID: 17365928 [TBL] [Abstract][Full Text] [Related]
18. [Study on the assay of uremic protein-binding inhibitors: furan compound and hippuric acid]. Tanaka Y Nihon Jinzo Gakkai Shi; 1991 Jul; 33(7):643-51. PubMed ID: 1749115 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of glyoxal and methylglyoxal levels in uremic patients under peritoneal dialysis. Lapolla A; Flamini R; Lupo A; Aricò NC; Rugiu C; Reitano R; Tubaro M; Ragazzi E; Seraglia R; Traldi P Ann N Y Acad Sci; 2005 Jun; 1043():217-24. PubMed ID: 16037242 [TBL] [Abstract][Full Text] [Related]
20. [Evaluation of polyneuropathy severity in chronic renal failure patients on continuous ambulatory peritoneal dialysis or on maintenance hemodialysis]. Janda K; Stompór T; Gryz E; Szczudlik A; Drozdz M; Kraśniak A; Sułowicz W Przegl Lek; 2007; 64(6):423-30. PubMed ID: 18159852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]